These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32523115)

  • 1. Cytokines that target immune killer cells against tumors.
    Qiao J; Fu YX
    Cell Mol Immunol; 2020 Jul; 17(7):722-727. PubMed ID: 32523115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation cytokines for cancer immunotherapy.
    Xue D; Hsu E; Fu YX; Peng H
    Antib Ther; 2021 Apr; 4(2):123-133. PubMed ID: 34263141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive therapies: quo vadis?
    Clark JW; Longo DL
    Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
    Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
    Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity.
    Leonard EK; Tomala J; Gould JR; Leff MI; Lin JX; Li P; Porter MJ; Johansen ER; Thompson L; Cao SD; Hou S; Henclova T; Huliciak M; Sargunas PR; Fabilane CS; Vaněk O; Kovar M; Schneider B; Raimondi G; Leonard WJ; Spangler JB
    JCI Insight; 2024 Sep; 9(18):. PubMed ID: 39115939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-21: a pleiotropic cytokine with potential applications in oncology.
    Croce M; Rigo V; Ferrini S
    J Immunol Res; 2015; 2015():696578. PubMed ID: 25961061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review.
    Phung CD; Tran TH; Kim JO
    Arch Pharm Res; 2020 Jan; 43(1):32-45. PubMed ID: 31993969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential and promise of IL-15 in immuno-oncogenic therapies.
    Robinson TO; Schluns KS
    Immunol Lett; 2017 Oct; 190():159-168. PubMed ID: 28823521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Killer Cells: Development, Maturation, and Clinical Utilization.
    Abel AM; Yang C; Thakar MS; Malarkannan S
    Front Immunol; 2018; 9():1869. PubMed ID: 30150991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of cancer by IL-12-based cytokine combinations.
    Weiss JM; Subleski JJ; Wigginton JM; Wiltrout RH
    Expert Opin Biol Ther; 2007 Nov; 7(11):1705-21. PubMed ID: 17961093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.
    Fewkes NM; Mackall CL
    Cancer J; 2010; 16(4):392-8. PubMed ID: 20693852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cells and cancer therapy, what we know and where we are going.
    Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
    Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaphorin 7A modulates cytokine-induced memory-like responses by human natural killer cells.
    Ghofrani J; Lucar O; Dugan H; Reeves RK; Jost S
    Eur J Immunol; 2019 Aug; 49(8):1153-1166. PubMed ID: 31016720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.
    Eriksen KW; Søndergaard H; Woetmann A; Krejsgaard T; Skak K; Geisler C; Wasik MA; Odum N
    Mol Immunol; 2009 Feb; 46(5):812-20. PubMed ID: 18947877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.